FDA's draft guidance on laboratory-developed tests increases clinical and economic risk to adoption of pharmacogenetic testing. - PubMed - NCBI

FDA's draft guidance on laboratory-developed tests increases clinical and economic risk to adoption of pharmacogenetic testing. - PubMed - NCBI

J Clin Pharmacol. 2015 Jul;55(7):725-7. doi: 10.1002/jcph.492.

FDA's draft guidance on laboratory-developed tests increases clinical and economic risk to adoption of pharmacogenetic testing.

Levy KD1, Pratt VM2, Skaar TC1, Vance GH3, Flockhart DA1,4.

Author information

PMID:

 

26053647

 

[PubMed - in process]